Michael Sørensen And Peter Ott - Nanotechnology

Author Information

Michael Ott is a distinguished researcher affiliated with the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School in Hannover, Germany. Additionally, he is associated with the Twincore Centre for Experimental and Clinical Infection Research, also located in Hannover, Germany. His research primarily focuses on liver diseases, including liver fibrosis, hepatocellular carcinoma, and the role of microRNAs and mRNA therapeutics.

Research Contributions

Michael Ott has made significant contributions to the field of liver disease research. His work includes pioneering studies on mRNA therapeutics for liver diseases, focusing on the delivery of HNF4A mRNA via lipid nanoparticles to attenuate liver fibrosis. He has also explored the role of microRNAs in modulating SARS-CoV-2 infection in primary human hepatocytes and investigated novel therapeutic approaches such as adeno-associated virus (AAV) vectors targeting hepatocellular carcinoma. His research has been published in high-impact journals, contributing valuable insights into the molecular mechanisms underlying liver diseases and potential therapeutic strategies.

Aliases

Michael Ott is also known by the following aliases: M Ott, M. Ott, Michael S. Ott, and Michael Sørensen And Peter Ott.

Publication and Citation Metrics

Metric	Value
Citation Count	6524
h-index	43
Paper Count	152

Publications:

Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].

DOI: 10.1016/j.jhep.2022.03.023

Year: 2022

mRNA therapeutics for liver diseases: HNF4A mRNA delivery via lipid nanoparticles attenuates liver fibrosis in preclinical models.

DOI: 10.1055/s-0041-1740682

Year: 2022

Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].

DOI: 10.1016/j.jhep.2022.03.022

Year: 2022

MicroRNAs modulate SARS-CoV-2 infection in primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2

DOI: 10.1055/s-0041-1740800

Year: 2022

Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors

DOI: 10.3390/cancers14020427

Year: 2022

Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.

DOI: 10.1016/j.jhep.2021.08.011

Year: 2021

Functional Genomic Screening During Somatic Cell Reprogramming Identifies DKK3 as a Roadblock of Organ Regeneration

DOI: 10.1002/advs.202100626

Year: 2021

Correction: Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B

DOI: 10.1371/journal.pgen.1009345

Year: 2021

Direct conversion of porcine primary fibroblasts into hepatocyte-like cells

DOI: 10.1038/s41598-021-88727-1

Year: 2021

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells

DOI: 10.1016/s0168-8278(20)31499-9

Year: 2020

What Role Do Nanomaterials Play in Petrochemical Applications?

How Does Radar Technology Work?

What are Accelerated Aging Tests?

How Can Nanotechnology Aid in Early Disease Detection?

What Are OLEDs and How Do They Benefit from Nanotechnology?

What are Engineered Proteins?

What Tools and Software are Commonly Used?

Why is Encapsulation Important?

What Challenges Do Researchers Face in Collaborative Nanotechnology Projects?

What Are Exchange Interactions?

Partnered Content Networks

Relevant Topics